Nomethiazoles Harnessing GABA and NO mimetic activity for Alzheimer's therapy

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R41AG044024-01A1
Agency Tracking Number: R41AG044024
Amount: $149,847.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIA
Solicitation Number: PA12-089
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
70 WALNUT ST, STE 302, WELLESLEY, MA, 02481-2102
DUNS: 941578564
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 GREGORY THATCHER
 (312) 355-5282
 thatcher@uic.edu
Business Contact
 JIA MD
Phone: (630) 324-6375
Email: jia_luo@hotmail.com
Research Institution
 UNIVERSITY OF ILLINOIS AT CHICACO
 UNIVERSITY OF ILLINOIS AT CHICAGO
310 AOB, M/C 672 1737 West Polk Street
CHICAGO, IL, 60612-
 () -
 Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) occurs in one out of eight Americans of age 65 and affects 43% of the elderly over 85. Current FDA-approved drugs only provide symptomatic relief of AD. There is a pressing need to discover newdisease-modifying medications. AD is multifactorial in origin and progression. A drug attenuating several underlying factors is a preferred therapy for AD. Nomethiazoles are a class of small molecules that address synaptic dysfunction through NO/cGMP signaling and harness the neuroprotective and GABA-mimetic activities of a methylthiazole (MZ) pharmacophore. Activation of the NO/cGMP/CREB signaling oathway, essential for learning and memory, is known to be attenuated in AD brains. The MZ pharmacophore provides neuroprotection against excitotoxicity and anti-inflammatory actions in the brain. Preliminary data show that nomethiazoles reverse cognitive deficits, slow A accumulation, and provide a positive biomarker profile in AD transgenic mouse models: four nomethiazoles have been identified as promising leads for AD therapy. Selection of the preferred drug candidate and a back-up compound for development is the major objective of this STTR phase I study. Optimal pharmaceutical salts of nomethiazoles will be prepared in Aim 1. In Aim 2, drug candidate selection will be guided by drug metabolism and pharmacokinetics (DMPK) studies. Stability in human/rodent plasma and liver microsomes will be investigated and PK profiles generated for nomethiazole and MZ metabolite in brain and plasma after i.p. delivery to mice. In Aim 3, behavioral data will be collected on procognitive, anxiolytic, and sedative effects, to determine the therapeutic window between procognitive and sedative potency. Data comparison of Aims 2 and3 will provide PK/PD correlations. The objective of planned STTR phase 2 studies is to reduce the risk of failure in the clinic by collecting further efficacy and safety data prior to launching full IND-enabling ADMET studies. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Alzheimer's disease (AD) occurs in one out of eight Americans of age 65 and affects 43% of the elderly over 85 with as yet no effective therapeutic approach to slowing disease progression. Nomethiazoles, a new drug class, have shown excellent results in animal models of AD. This STTR Phase 1 proposal will aid in selecting the preferred nomethiazole to move forward towards clinical use as a disease-modifying agent in AD.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government